三阴性乳腺癌化疗疗效及预后分析  

Analysis on prognosis and response to chemotherapy of triplenegative breast cancer

作　　者：曹轶林[1] 徐李容[1] 屈元姣[1] 秦日昇[1] 陈熙[1] 彭丽芳[1] 申昊[1] 

机构地区：[1]广西壮族自治区第二人民医院肿瘤科,桂林541002

出　　处：《中国癌症防治杂志》2009年第1期47-48,52,共3页CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT

摘　　要：目的探讨三阴性乳腺癌化疗疗效及与预后的关系。方法147例晚期乳腺癌患者用免疫组化法筛选雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的三阴性乳腺癌,化疗方案为紫杉醇135mg/m^2(或多西他赛75mg/m^2)静注,d1;顺铂30mg/m^2,静滴,d1～3。21d为1个周期,2个周期后评价疗效,分析三阴性乳腺癌及非三阴性乳腺癌临床病理特征、疗效及预后。结果147例患者中20例(13.6%)为三阴性乳腺癌,三阴性乳腺癌原发灶大小与非三阴性乳腺癌的差异有统计学意义(P=0.042),余临床病理特征无明显差异;三阴性乳腺癌化疗有效率(55.0%)高于非三阴性乳腺癌(32.3%,P=0.048),但中位肿瘤进展时间分别为5.5月和6.5月。结论紫杉醇(或多西他赛)联合顺铂对三阴性乳腺癌较敏感,但中位肿瘤进展时间则劣于非三阴乳腺癌。Objective To evaluate the response to chemotherapy and the prognosis of triple-negative breast cancer （TNBC）by comparing to the non-TNBC. Methods 147 advanced breast carcinoma patients were defined negative expresions of estrogenr eceptor （ ER ）, progesterone receptor （ PR ） and human epidermal growth factor rector 2 （ Her-2 ） by immunohistochemistry. Paclitaxel or Docetaxel was administered intravenously at a dose of 135mg/m2 （ or 75 mg/m2 ） on dl, Cisplatin 30mg/m2 from d1 to d3. A treatment cycle was 21 days. After 2 cycles, the pathologic parameters,the treatment efficacy and the prognosis were compared between the patients of TNBC and non-TNBC. Results 20 of 147 patients （ 13.6% ） were TNBC. Patients of TNBC had higher overall response rate compared with non-TNBC （P = 0. 048 ）. The median progression free survial time in the patients of TNBC and non-TNBC were 5.5 months and 6.5 months respectively. There were significant difference between the two groups at primary tumor size （P =0. 042）. Conclusion Paclitaxel or Docetaxel combined with Cisplatin chemotherapy regimen was sensitive in TNBC, but the median progression free survial time was worse in this group.

关 键 词：乳腺肿瘤 雌激素受体 孕激素受体 表皮生长因子受体-2 化学疗法 

分 类 号：R737.9[医药卫生—肿瘤]